Survivin selectively modulates genes deregulated in human leukemia stem cells.
ITD-Flt3 mutations are detected in leukemia stem cells (LSCs) in acute myeloid leukemia (AML) patients. While antagonizing Survivin normalizes ITD-Flt3-induced acute leukemia, it also impairs hematopoietic stem cell (HSC) function, indicating that identification of differences in signaling pathways downstream of Survivin between LSC and HSC are crucial to develop selective Survivin-based therapeutic strategies for AML. Using a Survivin-deletion model, we identified 1,096 genes regulated by Survivin in ITD-Flt3-transformed c-kit(+), Sca-1(+), and lineage(neg) (KSL) cells, of which 137 are deregulated in human LSC. Of the 137, 124 genes were regulated by Survivin exclusively in ITD-Flt3(+) KSL cells but not in normal CD34(neg) KSL cells. Survivin-regulated genes in LSC connect through a network associated with the epidermal growth factor receptor signaling pathway and falls into various functional categories independent of effects on apoptosis. Pathways downstream of Survivin in LSC that are distinct from HSC can be potentially targeted for selective anti-LSC therapy.
Department of Pediatrics, Shimane University School of Medicine, 89-1 Enya-Cho, Izumo, Shimane 693-8501, Japan.
Seiji
S
Fukuda
Mariko
M
Abe
Chie
C
Onishi
Takeshi
T
Taketani
Jamiyan
J
Purevsuren
Seiji
S
Yamaguchi
Edward M
EM
Conway
Louis M
LM
Pelus
Nat Genet. 1999 Dec;23(4):387-8
10581018
Blood. 2004 Jan 1;103(1):120-7
12969960
Cancer Invest. 2007 Dec;25(8):678-84
18058462
Mol Biol Cell. 2002 Sep;13(9):3064-77
12221116
Blood. 2009 Jul 9;114(2):394-403
19411632
Cancer Res. 2005 May 1;65(9):3531-4
15867343
Cell Cycle. 2002 Sep-Oct;1(5):322-6
12461294
Mol Cancer Ther. 2006 May;5(5):1087-98
16731740
J Biol Chem. 2003 Jan 3;278(1):486-90
12419797
Br J Haematol. 2000 Oct;111(1):196-203
11091201
Blood. 2005 Jul 15;106(2):673-80
15797998
Exp Hematol. 2008 Nov;36(11):1449-60
18687517
Blood. 2002 Jan 1;99(1):310-8
11756186
Cell. 1999 Apr 2;97(1):99-109
10199406
Int J Oncol. 2003 Jan;22(1):59-64
12469185
Blood. 2002 Oct 1;100(7):2463-71
12239157
Nat Protoc. 2009;4(1):44-57
19131956
Blood. 2001 May 1;97(9):2784-90
11313272
Nat Protoc. 2007;2(10):2366-82
17947979
J Immunol. 2004 Mar 15;172(6):3922-9
15004200
Science. 2002 Oct 18;298(5593):601-4
12228721
Mol Cell Biol. 2002 Aug;22(16):5688-97
12138181
Nat Rev Cancer. 2003 Jan;3(1):46-54
12509766
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5240-5
12682297
Blood. 2002 Sep 1;100(5):1532-42
12176867
Oncogene. 2003 Nov 24;22(53):8581-9
14634620
J Clin Oncol. 2010 Jul 10;28(20):3366-79
20530283
Blood. 2008 Feb 15;111(4):2170-80
17925489
Nat Rev Clin Oncol. 2010 May;7(5):251-65
20351699
J Exp Med. 2007 Jul 9;204(7):1603-11
17576776
Genes Dev. 2000 Dec 1;14(23):3003-13
11114889
Mol Cell. 2000 Jun;5(6):905-15
10911985
Blood. 2001 Oct 1;98(7):2091-100
11567995
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3396-401
19218430
Cancer Cell. 2009 Oct 6;16(4):281-94
19800574